about
Growth and Mortality Outcomes for Different Antiretroviral Therapy Initiation Criteria in Children Ages 1-5 Years: A Causal Modeling AnalysisVirologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysisPrognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: a collaborative analysis of treatment programsOutcomes of Infants Starting Antiretroviral Therapy in Southern Africa, 2004-2012.Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis.Growth of HIV-Exposed Uninfected Infants in the First 6 Months of Life in South Africa: The IeDEA-SA Collaboration.The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy.First-line antiretroviral drug discontinuations in childrenIncidence of AIDS-defining and Other Cancers in HIV-positive Children in South Africa: Record Linkage StudyPoor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.Timing of maternal HIV testing and uptake of prevention of mother-to-child transmission interventions among women and their infected infants in Johannesburg, South Africa.Reducing CD4 Monitoring in Children on Antiretroviral Therapy With Virologic Suppression.Improving early identification of HIV-infected neonates with birth PCR testing in a large urban hospital in Johannesburg, South Africa: successes and challengesPrevalence and outcomes of HIV-1 diagnostic challenges during universal birth testing - an urban South African observational cohort.Xpert HIV-1 point-of-care test for neonatal diagnosis of HIV in the birth testing programme of a maternity hospital: a field evaluation study.Brief Report: Pediatric Cancer Burden and Treatment Resources Within the Pediatric IeDEA Consortium.Despite Access to Antiretrovirals for Prevention and Treatment, High Rates of Mortality Persist Among HIV-infected Infants and Young Children.Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants.
P50
Q33619587-FBA9E198-E4CC-4DD0-999D-E9C5B53CE9A5Q33624953-66F60A65-8046-4A1D-BB24-55234D27E827Q35148237-80655F4B-12B5-463E-B57D-A22DE1D30DF7Q35872045-12360EFD-95D2-4B3A-825C-1DA73711BF19Q35965344-E5A4F0AD-954F-4EDE-A94E-5EC44FDEFC43Q35980844-478DA004-4EB8-4054-BFD0-DE3F0F6358DCQ36032235-05CDF6D0-AC28-4BB7-BF59-8C8C7DE3AAFBQ36278763-ED619D26-4318-49C3-8D47-896F5C82562BQ36896718-4A8C6DBD-A1CA-4E37-A263-8F6A159E8D99Q37029110-5558983E-4696-414B-98CD-3C8A075FF0A8Q37723043-ECF57541-7DC9-40F9-A1F1-8473D155468BQ37742040-17059608-C733-4F0E-92B0-347B3EF7BCF3Q38838564-D26210FF-1BDA-4B24-9A2A-B6BFD9C294FBQ40057847-A4351910-C2EE-4CBA-AC7B-6B48EA84115EQ40121496-47DCF2DC-5BFE-4FDD-933C-3730A946F696Q40196913-5F45BC33-A11B-49A2-BDBD-B5AE71A1564EQ40394069-36138A17-E5F1-4599-9059-6DF4B9596FF0Q40458484-F1BAC0D1-DDCB-4E41-9FA3-527C1F351F56
P50
description
onderzoeker
@nl
name
Karl-Günter Technau
@ast
Karl-Günter Technau
@en
Karl-Günter Technau
@nl
Karl-Günter Technau
@sl
type
label
Karl-Günter Technau
@ast
Karl-Günter Technau
@en
Karl-Günter Technau
@nl
Karl-Günter Technau
@sl
prefLabel
Karl-Günter Technau
@ast
Karl-Günter Technau
@en
Karl-Günter Technau
@nl
Karl-Günter Technau
@sl